With increased understanding of molecular alterations in NSCLC, recent research has shown a number of signaling nodes are activated within signaling pathways. Targeting molecular alterations individually, however, often leads to suboptimal responses, and inevitable resistance mechanisms. Integration of targeted therapies with cytotoxic agents, as well as novel combinations of targeted therapies, is hoped to further increase therapeutic potential of single-agent inhibitor strategies. We explored a database of theranostic biomarker
frequencies in NSCLC adenocarcinomas to explore the overlapping events that may result in potential novel combination strategies.